medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2005, Número 1

<< Anterior Siguiente >>

Rev Invest Clin 2005; 57 (1)


Farmacocinética poblacional de carbamacepina en pacientes epilépticos adultos

Romano-Moreno S, Medina-Rojas EL, Salas-Ortiz AL, Vargas-Morales JM, Pérez-Urizar JT, Rodríguez-Leyva I

Idioma: Español
Referencias bibliográficas: 44
Paginas: 38-48
Archivo PDF: 98.78 Kb.


RESUMEN

El objetivo de este trabajo es determinar los factores que influyen en el aclaramiento (CL) de carbamacepina (CBZ) en pacientes epilépticos adultos usando un modelo de efectos mixtos y datos de concentraciones séricas de CBZ generados del cuidado rutinario de los pacientes. El número de pacientes incluidos en el estudio fue de 104. Se analizaron un total de 161 concentraciones séricas de CBZ en el estado estacionario. El aclaramiento poblacional se determinó con el programa NONMEM aplicando un modelo monocompartimental con absorción y eliminación de primer orden. Se analizó la influencia de las siguientes covariables sobre el CL: peso corporal total, edad, dosis/día, sexo, superficie corporal (SC) y la comedicación con primidona (PRIM), ácido valproico o difenilhidantoína (DFH). El modelo final de regresión obtenido es el siguiente: CL = (0.614 SC + 0.0016 dosis/día)( 1+ 0.278 DFH)(1+ 0.326 PRIM).


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Goodman GA. Las bases farmacológicas de la terapéutica. Vol. 1. 9a. edición. España: Editorial Panamericana; 2000, p. 491-506.

  2. Spina E, Pisani F, Perucca E. Clinically significant pharmacokinetic drug interactions with carbamazepine. An update. Clin Pharmacokinet 1996; 31: 198-214.

  3. MacKichan JJ. Carbamazepine. In: Taylor WJ, Diers Caviness MH (Ed). A textbook for the clinical application of therapeutic drug monitoring. Irving, Texas: Abbott Laboratories, Diagnostic Division; 1986, p. 211-22.

  4. Battino D, Estienne M, Avanzini G. Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part II: Phenytoin, Carbamazepine, Sultiame, Lamotrigine, Vigabatrin, Oxcarbamazepine and Felbamate. Clin Pharmacokinet 1995; 29: 341-69.

  5. Liu H, Delgado MR. Influence of sex, age, weight and carbamazepine dose on serum concentrations, concentration ratio and level/dose ratios of carbamazepine and its metabolites. Ther Drug Monit 1994; 16: 469-76.

  6. Martin ES, Crismon ML, Godley PJ. Postinduction carbamazepine clearance in adult psychiatric population. Pharmacotherapy 1991; 11: 296-302.

  7. Reith DM, Hooper W, Parke J, Charles B. Population pharmacokinetic modeling of steady state carbamazepine clearance in children, adolescents and adults. J Pharmacokinet Biopharm 2001; 28: 79-92.

  8. Summers B, Summers RS. Carbamazepine clearance in paediatric epilepsy patients: Influence of body mass, dose, sex and co-medication. Clin Pharmacokinet 1989; 17: 208-16.

  9. Suzuki Y, Cox S, Hayes J, Walson PD. Carbamazepine age-dose ratio relationship in children. Ther Drug Monit 1991; 13: 201-8.

  10. Sheiner LB, Grasela TH. An introduction to mixed effect mod-eling: concepts, definitions and justification. J Pharmacokinet Biopharm 1991; 19: 11S-24S.

  11. Grasela TH, Sheiner LB. Pharmacostatistical modelling for observational data. J Pharmacokin Biopharm 1991; 19: 25S-36S.

  12. Karlsson MO, Thomson AH, McGovern EM, Chow P, Evan TJ, Kelman AW. Population pharmacokinetics of rectal theophyl-line in neonates. Ther Drug Monit 1991; 13: 1995-2000.

  13. Romano S, Fernández de Gatta MM, Calvo V, Méndez E, Dominguez-Gil A, Lanao JM. Population pharmacokinetics of amikacin in patients with haematological malignancies. J Antimic Chemother 1999; 44: 235-42.

  14. Serrano BB, García-Sánchez MJ, Otero MJ, Buelga DS, Serrano J, Domínguez-Gil A. Valproate population pharmacokinetics in children. J Clin Pharm Ther 1999; 24: 73-80.

  15. Delgado I, Santos B, García MJ, Otero MJ, Falcao AC, Domínguez-Gil A. Carbamazepine population pharmacokinetics in children: Mixed-Effect Models. Ther Drug Monit 1997; 19: 132-9.

  16. Chan E. Population pharmacokinetics of carbamazepine in Singapore epileptic patients. Br J Clin Pharmacol 2001; 51: 567-76.

  17. Yukawa E, Aoyama T. Detection of carbamazepine drug inter-action by multiple peak approach screening using routine clinical pharmacokinetic data. J Clin Pharmacol 1996; 36: 752-9.

  18. Graves NM. Population pharmacokinetics of carbamazepine in adults with epilepsy. Pharmacotherapy 1998; 18: 273-81.

  19. Deleu D, Aarons L, Ahmed IA. Population pharmacokinetics of free carbamazepine in adult Omani epileptic patients. Eur J Clin Pharmacol 2001; 57: 243-8.

  20. Zheng JZ, Zhong MK, Shi XJ, Hu M, Zhang JH. Population pharmacokinetics of carbamazepine in Chinese epilepsy patients. Ther Drug Monitor 2003; 25: 279-86.

  21. Secretaría de Salud. Cuadro Básico y Catálogo de Medicamentos. Comisión Interinstitucional del Cuadro Básico de Insumos del Sector Salud. www.salud.gob.mx/unidades/csg/cuads_bas_cat2002/medica_2004.htm; 2004, p. 14-22.

  22. Morselli PJ. Carbamazepine. Absorption, distribution and excretion. In: Levy RH, Dreifuss LE, Mattson RH, Meldrum BS, Penry JK, eds. Antiepileptic Drugs. Third Edition. New York (USA): Raven Press. Ltd.; 1989 p. 473-90.

  23. Sheiner LB, Beal SL. Evaluation of methods for estimating population pharmacokinetic parameters. III. Monoexponential model: routine clinical pharmacokinetic data. J Pharmacokinet Bipharm 1983; 11: 303-19.

  24. Whiting B, Kelman AW, Grevel J. Population pharmacokinetics. Theory and clinical application. Clin Pharmacokinet 1986; 11: 387-401.

  25. Pynnönen S. Pharmacokinetics of carbamazepine in man: A review. Ther Drug Monitor 1979; 1: 409-31.

  26. Mosteller RD. Simplified calculation of body-surface area. New Engl J Med 1987; p. 1098.

  27. Beal SL, Sheiner LB. NONMEM User’s Guide, Part V: Introductory Guide. NONMEM Project Group. San Francisco: University of California; 1992.

  28. Grasela TH. Population pharmacokinetics: application to clinical trials. In: Smith RB. Kroboth PD, Juhl RP, eds. Pharmacokinetics and pharmacodynamics. Research design and analysis. Cincinnati: Harvey Witney Books (USA); 1986, p. 85-103.

  29. Lee P. Design and power of a population pharmacokinetic study. Pharmaceutical Research 2001; 18: 75-82.

  30. Hartley R, Lucock MD, Forsythe WI, McLain B. Factors influencing plasma level/dose ratios of carbamazepine and its major metabolites in epileptic children. Ther Drug Monit 1990; 12: 438-44.

  31. Kumps A. Dose dependency between carbamazepine serum lev-els and dosage in patients with epilepsy. Ther Drug Monit 1981; 3: 271-4.

  32. Sánchez A, Duran JA, Serrano JS. Steady-state carbamazepine plasma concentration-dose ratios in epileptic patients. Clin Pharmacokinet 1986; 11: 283-6.

  33. Lack JA, Stuart ME. Calculation of drug dosage and body surface area of children. Br J Anaesth 1997; 78: 601-5.

  34. Carles J, Kohen E, Midy D, Saric J, Videau J. Appréciation du volume hépatique en function de la morphologie de l’individu. Bull Assoc Anatom 1993; 77: 9-13.

  35. De Land FH, North WA. Relationship between liver size and body size. Radiology 1968; 91: 1195-8.

  36. Battino D, Bossi L, Croci D, Francechetti S, Gomeni C. Carbamazepine plasma levels in children and adults: Influence of age, dose, and asociated therapy. Ther Drug Monit 1980; 2: 315-22.

  37. Lanchote V, Bonato P, Campo G, Rodrigues E. Factors influencing plasma concentrations of carbamazepine and carbamazepine-10-11-epoxide in epileptic children and adults. Ther Drug Monit 1995; 17: 47-52.

  38. Bertilsson L, Tomson T. Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10,11-epoxide. Clin Pharmacokinet 1986; 11: 177-98.

  39. Eichelbaum M, Kothe KW, Hoffman F, Van Unruh G. Kinetic and metabolism of carbamazepine during combined antiepileptic drug therapy. Clin Pharmacol Ther 1979; 26: 366-71.

  40. Rambeck B, May T, Juergens U. Serum concentrations of carbamazepine and its epoxide and diol metabolites in epileptic patients: the influence of dose and co-medications. Ther Drug Monit 1987; 9: 198-203.

  41. Riva A, Contin M, Albani F. Free concentration of carbamazepine and carbamazepine-10-11-epoxide in children and adults: influence of age and phenobarbitone co-medication. Clin Pharmacokin 1985; 10: 524-31.

  42. Levy RH, Bradley MK. Clinical pharmacokinetics of carbamazepine. J Clin Psychiatry 1988; 49(Suppl.4): 58-62.

  43. Baciewicz AM. Carbamazepine drug interaction. Ther Drug Monit 1986; 8: 305-17.

  44. Chang SL, Levy RH. Inhibitory effect of valproic acid on the disposition of carbamazepine and carbamazepine-10-11-epoxide in the rate. Drug Metabol Dispos 1986; 14: 281-6.




2020     |     www.medigraphic.com